Metopimazine Sans Sucre, Édulcoré À L’aspartam Venipharm (Metopimazine)

Metopimazine acts as a dopamine D2 receptor antagonist with additional anticholinergic properties. By inhibiting dopamine signaling in the chemoreceptor trigger zone and reducing cholinergic activity, it dampens the neural pathways that initiate nausea and vomiting, thereby decreasing the frequency and severity of these symptoms.

The dose of Metopimazine is individualized by the prescribing clinician based on the patient’s condition, age, and response to therapy. Healthcare professionals determine the appropriate strength and frequency, and patients should follow the prescriber’s instructions without deviation.

The safety of Metopimazine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metopimazine belongs to the phenothiazine class, offering dopamine antagonism similar to other agents like prochlorperazine. Compared with serotonin‑type antiemetics (e.g., ondansetron), Metopimazine may have a broader anticholinergic profile, which can be advantageous in certain postoperative settings but may also increase anticholinergic side effects.

Metopimazine Sans Sucre should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s stability and potency throughout its shelf life.

Metopimazine is taken orally as a tablet. The tablet should be swallowed whole with water, preferably on an empty stomach or as directed by the prescriber. Patients should not crush, chew, or split the tablet unless specifically instructed.

Serious risks include extrapyramidal symptoms such as dystonia or akathisia, neuroleptic malignant syndrome, severe hypotension, cardiac arrhythmias, and rare allergic reactions. Patients should be monitored for any signs of these conditions and seek immediate medical attention if they occur.

Metopimazine is contraindicated in individuals with known hypersensitivity to phenothiazine derivatives. Caution is also advised for patients with severe cardiovascular disease, uncontrolled hypertension, or a history of neuroleptic malignant syndrome. The drug should be avoided in these populations unless a specialist determines that benefits outweigh the risks.